som saa is a unique cocktail bar and restaurant located in Spitalfields, London. It serves high quality regional Thai cuisines made with uncompromising flavours. som saa has more than 27,000 followers on Instagram and carries a loyal customer following. In 2016, som saa became the Restaurant of the Year sponsored by The London Restaurant Festival. It is planning to open a second restaurant in Central London. Approximately 32.5% of the proceeds will be used for building and direct works; 20% will be used for kitchen design, building, and extraction; 14% will be used for professional fees; 5% for bar installation; and 28.5% other opening costs.
days to go:
Expired
investment:
£253,633
Big Night is an online food delivery service that partners with selected independent food vendors to deliver exceptional meals to customers at home, in their office or wherever they choose. The company asserts that 61% of non-millennials find delivery overall frustrating. Big Night aims to change this scenario. It has signed on ten notable restaurants and has ten more in the immediate pipeline. Onboarded restaurants include Two Lights, Luca, The Laughing Heart, Sager + Wilde, Royale, Levan, AngloThai, Legare and Mangal2. Over 4,000 people have ordered via Big Night since its launch. The company will use 25% of the investment for operations, 25% for marketing, and 50% to improve the Big Night platform.
days to go:
Expired
investment:
£274,168
Market Halls (MH) takes unloved public spaces and transforms them into destinations for all-day drinking and dining. MH claims to offer something for everyone, taking visitors seamlessly from breakfast through to late-night snacks. It argues that it has established three venues in Fulham, Victoria and the West End that have attracted crowds in excess of 1.04 million in 2019. MH asserts that it received a Net Promoter Score (NPS) of 62, generated £15 million in revenue in 2020, and has featured in publications such as The Telegraph, The Guardian and Independent. MH also stresses that it has a ‘Best in Class’ retention rate of 80% repeat business. It states it will use the investment to scale up its business with a new identity, new gold-dust venues and an improved customer offering.
days to go:
Expired
investment:
£787,240
TC BioPharm is an immunotherapy company. It has used its patented technology to harness the power of a particular part of the immune system, Gamma Delta T-cells (GDT), to negate cancer cells in the human body. TC BioPharm has treated terminally ill patients with acute myeloid leukaemia in approved clinical trials garnering positive responses from multiple patients. The company has received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to run a COVID-19 clinical trial to address the global pandemic. TC BioPharm aims to use its current technology to provide a frozen product that can be manufactured cost-effectively and distributed globally. The company has already raised over £7 million in the last 15 months. It will use the investment to take its clinical trials forward in COVID-19 and cancer.
days to go:
Expired
investment:
£1,753,067
Noveltea is a premium alcoholic tea brand launched in Fenwick in April 2017. The company's products are vegan, gluten-free and low in sugar, and manufactured in minimalistic & up-cyclable lifestyle packaging. Thanks to its low-Alcohol by volume (ABV) portfolio, the brand has sold 350,000 bottles since its launch in 2017. The company experienced more than £100,000 worth of sales in April 2020 despite COVID-19 due to smart e-commerce channel utilisation. In 2020, the size of the global alcoholic drinks market is $1.587 trillion and is forecasted to grow by 3.5% (CAGR) over the next three years. The brand aims to become a major contender in this segment and grow its business. The company use the investment to focus on its core markets in the UK, Germany, and China, and enter the USA by 2020.
days to go:
Expired
investment:
£558,845
Mr Lee’s Pure Foods is an innovative food/tech company creating award-winning premium healthy noodles-in-a-cup and will be launching its new instant Congee Asian rice porridge. All products are certified low sugar, gluten-free, low on calories, Vegan options and 100% recyclable and compostable packaging. The global instant noodle market is expected to reach $57.5 billion by 2024 which the brand aims to capitalise on and establish itself in as the market leader. Mr Lee's has won 50+ global awards and nominations including Grocer Gold Exporter of the Year, Great British Entrepreneur winner, and The Sunday Times Maserati 100 winner. Noted publisher Penguin Random House has published Mr Lee’s 100 Noodle Recipe cookbook which has been met with critical acclaim worldwide. With the investment, the company will invest 25% of it in marketing initiatives and entering into the US market, 10% in product development, 20% in working capital for food production during scale-up, 5% in upgrading its Hot Noodle Kiosk and vending machine facilities, and 40% in global group operating and personnel costs runway for commercial functions and scale-up activities within Australia, the UK, and the USA.
days to go:
Expired
investment:
£1,835,892
Coconuts Organic is a company that produces plant-based ice creams. Coconuts Organic asserts that it is one of only two mainstream organic plant-based ice cream brands in the UK. The company aims to tap into the fast-growing global trend of healthier eating and sustainable food. Coconuts Organic has won seven Great Taste Awards and became the fastest-growing 'Wellness Ice Cream' brand in the UK according to a May 2020 Nielsen report. Its products are stocked in major retail chains like M&S and Ocado. The company will use the investment to grow its sales and marketing team, increase its eCommerce business, scale its operations, and invest in marketing activity that will create consumer demand.
days to go:
Expired
investment:
£327,979
ByRuby is a food delivery company. It sources produce from local ethical suppliers, prepares meals in small batches using the raw produce, freezes the meal to preserve the taste, and delivers it nationwide. ByRuby argues that the UK ready meal sales market is worth £12 billion in 2020. The company witnessed sales up to 200% online in March 2020. ByRuby asserts that it uses only British free-range or organic meat & sustainably sourced fish from British waters. The company won the 2018 Women's Health Food Award. Its products are stocked in 26 retail stores. ByRuby has been mentioned by publications such as Daily Mail, Daily Telegraph, and Metro. It will use 50% of the investment for marketing, 26% to grow its kitchen team, 17% to upgrade its kitchen and 7% for new product development.
days to go:
Expired
investment:
£288,243
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
